EPDR1 is related to stages and metastasize in bladder cancer and can be used as a prognostic biomarker

  • BMC Urol. 2021 Apr 26;21(1):71. doi: 10.1186/s12894-021-00843-2.
Yue Yang  1  2  3 ,  Hanchao Zhang  1  2  3 ,  Zhengdao Liu  1  3 ,  Faliang Zhao  1  3 ,  Guobiao Liang  4  5
Affiliations
  • 1. Medical College of Soochow University, Suzhou, Jiangsu, China.
  • 2. Urological Department, The Affiliated Hospital and Clinical Medical College of Chengdu University, Chengdu, Sichuan, China.
  • 3. Urological Department, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
  • 4. Medical College of Soochow University, Suzhou, Jiangsu, China. [email protected].
  • 5. Urological Department, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China. [email protected].
PMID: 33902536 DOI: 10.1186/s12894-021-00843-2
Abstract

Background: Bladder Cancer (BLCA) is a malignant urothelial carcinoma and has a high mortality rate. EPDR1 (ependymin related 1) is a type II transmembrane protein and related to calcium-dependent cell adhesion.

Methods: We explored the potential oncogenic roles of EPDR1 in BLCA basing on the multiple public datasets.

Results: We found that EPDR1 expression had a significant difference in BLCA and adjacent normal bladder tissues, and the level of EPDR1was up-regulated with advanced tumor stage and metastasis in BLCA. Meanwhile, the high expression group of EPDR1 had a shorter OS compared to the low or medium expression-group. Furthermore, EPDR1 expression was associated with tumor-infiltrating immune cells (TIICs), including NK cells, CD8 + T cells, CD4 + T cells, Macrophages cells, and so on. Moreover, EPDR1 also involved in several signaling pathways as well as PI3K/Akt pathway, Cytokine receptor interaction, and Apoptosis.

Conclusion: EPDR1 can be used as a novel prognostic biomarker as well as an effective target for diagnosis and treatment in BLCA.

Keywords
Biomarker; Bladder cancer; EPDR1; Immune cell infiltration.
Products